If peritoneal mesothelioma patients undergo a second surgery after recurrence, they can improve their survival. Data from a retrospective review from Wake Forest Baptist Medical Center shows that cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) can be incredibly helpful for peritoneal disease sufferers. For some people, a second surgery has[…]
Peritoneal Mesothelioma
ERAS® Guidelines Validation of CRS With or Without HIPEC
Primary Outcome Measures Compliance of ERAS® guidelines [ Time Frame: 3 months ] Post-ERAS® implementation phase: compliance rate towards the relevant core items from ERAS guidelines Secondary Outcome Measures Acceptance and feasibility of ERAS® guidelines [ Time Frame: 3 months ] Pre-ERAS® phase (current clinical practice): current compliance rate towards the ERAS guidelines Inclusion Criteria Adults female and[…]
Assessment of Histologic Prognostic Factors in Peritoneal Malignant Mesothelioma
Primary Outcome Measures Assessment of pronostic impact of nuclear grade in comparison with combined grade in peritoneal malignant mesothelioma [ Time Frame: 3 months to 4 years ] Assessment by the review of pathologists Inclusion Criteria peritoneal malignant mesothelioma Exclusion Criteria opposition to reuse personnal data
LMB-100 and Ipilumab Combination Being Tested for Pleural and Peritoneal Mesothelioma
The National Cancer Institute just started a study to see if it could make immunotherapy more potent for treating mesothelioma. The study combines a manmade protein that kills cancer cells called LMB-100 and an immunotherapy drug called ipilumab. The problem with current immunotherapy treatments is they do not work well[…]
A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma
Primary Outcome Measures Major Pathologic (Disease) Response of Tumor to Nivolumab Combined with Ipilimumab Before Surgery [ Time Frame: 24 months ] The response of participant’s tumor to treatment with nivolumab and ipilimumab before surgery by analyzing tissue samples collected from participant during surgery for the presence of cancerous tumour cells. Major pathologic response[…]
A Combination of Tremelimumab and Durvalumab Can Extend Mesothelioma Survival
An Italian study has found that the combination of two immunotherapy drugs can create a long-term survival in mesothelioma patients. The two drugs, tremelimumab and durvalumab, were just given orphan drug status to treat liver cancer in the last year. The best results in the mesothelioma study were seen in[…]
Second-Line Chemotherapy Could Help Some Peritoneal Mesothelioma Patients
Oncologists in Japan have found a way to determine which patients would best benefit from second-line chemotherapy. Second-line treatment is a second treatment that doctors perform after trying another treatment first. When the first treatment doesn’t work or stops working, a second-line treatment is tried to see if it will[…]
Peritoneal Mesothelioma Surgery with More organ Removal Can Help Survival
Mesothelioma surgery that removes more of an organ has been found to extend the survival of patients. It also did not increase the chance of severe complications nor did it change the survival benefits of aggressive surgery on patients with peritoneal mesothelioma. The complex surgery also did not negatively affect[…]
More Peritoneal Mesothelioma Patients Should be Receiving Surgery
Peritoneal mesothelioma is a rare condition with only 400 cases diagnosed every year. Patients diagnosed with the cancer are not living as long as they could because of the underutilization of surgery. Surgery is only performed on a third of patients even though there are people that would benefit and[…]
Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Malignant MESOthelioma (TALAMESO)
Primary Outcome Measures Non-progression proportion [ Time Frame: 6 month after starting talazoparib ] The non-progression proportion is defined as the proportion of patients free of progression 6 months after talazoparib start. Disease progression will be based on (i) tumor assessment made by the investigators according to the RECIST 1.1 criteria and/or, ii) non-equivocal[…]